Sordat B, Reiter L, Cajot J F
Unit of Experimental Pathology, Swiss Institute for Experimental Cancer Research, Epalinges.
Cell Differ Dev. 1990 Dec 2;32(3):277-85. doi: 10.1016/0922-3371(90)90040-4.
Gene transfer techniques were utilized to evaluate the role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in enhancing or preventing the expression of the invasive malignant phenotype, respectively. Mouse L-cell transfectants expressing human uPA or human PAI-1 as well as mouse B16 transfectants expressing mouse uPA or human PAI-1 were generated. These transfectants were tested using a variety of experimental methods including smooth muscle cell matrix solubilization in vitro, lung colony formation in vivo and co-cultures of antagonist-expressing cells in vitro. Results from these studies provide direct evidence for an enhancing role of uPA in malignant invasion and experimental metastasis and for a modulatory role of PAI-1 in tumor cell-mediated breakdown of extracellular matrices.
利用基因转移技术分别评估尿激酶型纤溶酶原激活剂(uPA)和纤溶酶原激活剂抑制剂1型(PAI-1)在增强或阻止侵袭性恶性表型表达中的作用。构建了表达人uPA或人PAI-1的小鼠L细胞转染子以及表达小鼠uPA或人PAI-1的小鼠B16转染子。使用多种实验方法对这些转染子进行测试,包括体外平滑肌细胞基质溶解、体内肺集落形成以及体外表达拮抗剂细胞的共培养。这些研究结果为uPA在恶性侵袭和实验性转移中的增强作用以及PAI-1在肿瘤细胞介导的细胞外基质降解中的调节作用提供了直接证据。